Marshall Wace, LLP Caribou Biosciences, Inc. Transaction History
Marshall Wace, LLP
- $90.8 Billion
- Q3 2025
A detailed history of Marshall Wace, LLP transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 125,844 shares of CRBU stock, worth $255,463. This represents 0.0% of its overall portfolio holdings.
Number of Shares
125,844Holding current value
$255,463% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding CRBU
# of Institutions
123Shares Held
39.9MCall Options Held
42.2KPut Options Held
93.2K-
Black Rock Inc. New York, NY6.95MShares$14.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.23MShares$8.58 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.22MShares$6.53 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.07MShares$6.23 Million0.6% of portfolio
-
Pictet Asset Management Sa Geneva 73, V81.81MShares$3.67 Million0.01% of portfolio
About Caribou Biosciences, Inc.
- Ticker CRBU
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,840,800
- Market Cap $124M
- Description
- Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...